Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Lipase inhibitors act on enzymes that hydrolyze ester bonds in triglycerides, diglycerides and monoglycerides. In adipose tissue, adipose triglyceride lipase (ATGL) starts lipolysis, a role reported in 2004. Hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MAGL) then complete the release of fatty acids. Atglistatin, described in 2013, inhibits ATGL, and HSL-IN-1 targets HSL. JZL184 blocks MAGL, which hydrolyzes the endocannabinoid 2-arachidonoylglycerol, and its 2009 report linked this to cannabinoid behavioral effects in mice. JZL195 inhibits MAGL together with fatty acid amide hydrolase (FAAH), covered in the FAAH category. KT109 targets diacylglycerol lipase beta (DAGLβ), and XEN445 inhibits endothelial lipase.
Ciwujianoside D2 is a natural saponin compound that acts as a pancreatic lipase activator. It enhances the enzymatic activity of pancreatic lipase in vitro, facilitating lipid digestion and metabolism. This compound can be utilized in research investigating obesity, metabolic disorders, and digestive enzyme regulation.
Ciwujianoside C4 is a saponin compound recognized for its activity as a pancreatic lipase activator. It enhances the enzymatic activity of pancreatic lipase in vitro, playing a crucial role in lipid metabolism. This compound is useful in research applications focused on understanding fat digestion and metabolic disorders related to lipid absorption.
